Literature DB >> 29247256

miR-498 promotes cell proliferation and inhibits cell apoptosis in retinoblastoma by directly targeting CCPG1.

Ling Yang1, Ning Wei2, Li Wang1, Xiang Wang1, Qing-Huai Liu3.   

Abstract

PURPOSE: Retinoblastoma (Rb) is the most common intraocular tumor in children. MicroRNAs (miRNAs) play a crucial role in gene regulation and cell growth/apoptosis/differentiation. The current study aimed to investigate the role of miR-498 in Rb.
METHODS: Quantitative real-time polymerase chain reaction (QRT-PCR) was used to test mRNA level of miR-498. http://www.targetscan.org and http://www.microrna.org were applied to predict target of miR-498. Dual-luciferase reporter assay was applied to investigate if miR-498 targeted cell cycle progression 1 (CCPG1). Western blot (WB) was carried out to assess CCPG1 protein levels. 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) assay was used to evaluate cell proliferation. Annexin-V Fluorescein (FITC) was adopted to explore cell apoptosis.
RESULTS: In Y79 cells, miR-498 was higher than in normal ARPE-19 cells. MiR-498 could recognize CCPG1-3' untranslated region (UTR). CCPG1 protein level was remarkably decreased when overexpressed miR-498, nevertheless, significantly increased when inhibiting miR-498. Y79 cells that were transfected with miR-498 mimics manifested notable cell apoptosis down-regulation and cell proliferation promotion; whereas, those transfected with miR-498 inhibitor displayed significant cell apoptosis up-regulation and cell proliferation inhibition compared with control group.
CONCLUSION: Taken together, miR-498 promotes cell proliferation and inhibits cell apoptosis in Rb by directly targeting CCPG1.

Entities:  

Keywords:  Cell cycle progression 1; Retinoblastoma; Y79 cell line; miR-498

Mesh:

Substances:

Year:  2017        PMID: 29247256     DOI: 10.1007/s00381-017-3622-8

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  28 in total

1.  Gene regulation by transcription factors and microRNAs.

Authors:  Oliver Hobert
Journal:  Science       Date:  2008-03-28       Impact factor: 47.728

Review 2.  Non-coding RNAs: regulators of disease.

Authors:  Ryan J Taft; Ken C Pang; Timothy R Mercer; Marcel Dinger; John S Mattick
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

Review 3.  ABC of eyes. Squint.

Authors:  A R Elkington; P T Khaw
Journal:  BMJ       Date:  1988-09-03

4.  Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.

Authors:  W K Cavenee; T P Dryja; R A Phillips; W F Benedict; R Godbout; B L Gallie; A L Murphree; L C Strong; R L White
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

5.  MiR-498 regulated FOXO3 expression and inhibited the proliferation of human ovarian cancer cells.

Authors:  Ruonan Liu; Fenghua Liu; Lei Li; Miaomiao Sun; Kuisheng Chen
Journal:  Biomed Pharmacother       Date:  2015-04-14       Impact factor: 6.529

6.  Diagnostic and prognostic microRNAs in stage II colon cancer.

Authors:  Troels Schepeler; Jørgen T Reinert; Marie S Ostenfeld; Lise L Christensen; Asli N Silahtaroglu; Lars Dyrskjøt; Carsten Wiuf; Frank J Sørensen; Mogens Kruhøffer; Søren Laurberg; Sakari Kauppinen; Torben F Ørntoft; Claus L Andersen
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  RNAi screen indicates widespread biological function for human natural antisense transcripts.

Authors:  Mohammad Ali Faghihi; Jannet Kocerha; Farzaneh Modarresi; Pär G Engström; Alistair M Chalk; Shaun P Brothers; Eric Koesema; Georges St Laurent; Claes Wahlestedt
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

8.  Incidence of retinoblastoma in the USA: 1975-2004.

Authors:  E Broaddus; A Topham; A D Singh
Journal:  Br J Ophthalmol       Date:  2008-07-11       Impact factor: 4.638

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

10.  Retinoblastoma in Great Britain 1963-2002.

Authors:  A MacCarthy; J M Birch; G J Draper; J L Hungerford; J E Kingston; M E Kroll; Z Onadim; C A Stiller; T J Vincent; M F G Murphy
Journal:  Br J Ophthalmol       Date:  2008-10-06       Impact factor: 4.638

View more
  8 in total

1.  Shikonin-mediated up-regulation of miR-34a and miR-202 inhibits retinoblastoma proliferation.

Authors:  Yan Su; Shiyou Lu; Jincun Li; Liya Deng
Journal:  Toxicol Res (Camb)       Date:  2018-06-06       Impact factor: 3.524

2.  MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.

Authors:  Yang Cheng; Wei Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

3.  The Potential Tumor Promotional Role of circVAPA in Retinoblastoma via Regulating miR-615-3p and SMARCE1.

Authors:  Qibin Xu
Journal:  Onco Targets Ther       Date:  2020-08-05       Impact factor: 4.147

4.  TMPO-AS1 promotes cell proliferation of thyroid cancer via sponging miR-498 to modulate TMPO.

Authors:  Zhenyu Li; Yun Feng; Zhen Zhang; Xiaozhong Cao; Xiubo Lu
Journal:  Cancer Cell Int       Date:  2020-07-08       Impact factor: 5.722

Review 5.  Expression profiles and prognostic value of miRNAs in retinoblastoma.

Authors:  Lara Elis Alberici Delsin; Karina Bezerra Salomao; Julia Alejandra Pezuk; Maria Sol Brassesco
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-22       Impact factor: 4.553

6.  Circ_0068655 Promotes Cardiomyocyte Apoptosis via miR-498/PAWR Axis.

Authors:  Qiaoying Chai; Mingqi Zheng; Le Wang; Mei Wei; Yajuan Yin; Fangfang Ma; Xinping Li; Haijun Zhang; Gang Liu
Journal:  Tissue Eng Regen Med       Date:  2020-08-06       Impact factor: 4.169

Review 7.  Hypoxia and Selective Autophagy in Cancer Development and Therapy.

Authors:  Ioanna Daskalaki; Ilias Gkikas; Nektarios Tavernarakis
Journal:  Front Cell Dev Biol       Date:  2018-09-10

Review 8.  ER-phagy in the Occurrence and Development of Cancer.

Authors:  Huimin Zhou; Kexin Wang; Mengyan Wang; Wenxia Zhao; Conghui Zhang; Meilian Cai; Yuhan Qiu; Tianshu Zhang; Rongguang Shao; Wuli Zhao
Journal:  Biomedicines       Date:  2022-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.